Coherus Has $2.2bn Revenue Ambition By 2026 – But Humira Is Key
Yusimry Adalimumab Biosimilar Uptake Is ‘Key Swing’ For Company Projections
During the company’s landmark first annual analyst day, Coherus BioSciences management spoke at length about its ambitions for Coherus to generate north of $2bn in revenues by 2026, with much riding on how it fares in the impending biosimilar Humira market.
